Tonix Pharmaceuticals Receives the US FDA’s IND Clearance of TNX-1500 for the Prevention of Organ Rejection in Kidney Transplant Patients
Shots:
- The US FDA has cleared an IND application to initiate the P-I trial in Q3’23 of TNX-1500 (Fc-modified anti-CD40L mAb) for the prevention of organ rejection in patients who received a kidney transplant. Patient enrolment is expected to initiate in Q3’23
- The application of TNX-1500 was based on the preclinical allotransplantation studies conducted at MGH. The company’s primary focus will be allotransplantation in which the donor organ comes from another human
- TNX-1500 was well tolerated & showed activity in preventing allograft organ rejection in preclinical studies on non-human primates. TNX-1500 helps to decrease FcγRIIA binding by protein engineering & reduce the potential for thrombosis while the therapy is in development for MS
Ref: Globenewswire | Image: Tonix
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
